Improvement of lenvatinib-induced nephrotic syndrome after adaptation to sorafenib in thyroid cancer: A case report

Yang, Che‐Hsueh; Chen, Kuo Tung; Yang, Lin; Hsu, Chao‐Yu; Ou, Yen Chuan; Tung, Min‐Che

doi:10.12998/wjcc.v8.i20.4883

Cited by 6 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TKI dose reduction also promotes the resolution of renal adverse events and successful DTC treatment continuation [ 64 ]. The replacement of Lenvatinib with Sorafenib may also be considered to reduce TKI nephrotoxicity [ 65 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Thyroid Cancer Treatment on Renal Function: A Relevant Issue to Be Addressed

Paola

Capasso

et al. 2023

JPM

View full text Add to dashboard Cite

Thyroid cancers require complex and heterogeneous therapies with different impacts on renal function. In our systematic literature review, we analyzed several aspects: renal function assessment, the impact of radiotherapy and thyroid surgery on kidney functioning, and mechanisms of nephrotoxicity of different chemotherapy, targeted and immunologic drugs. Our study revealed that the renal impact of thyroid cancer therapy can be a limiting factor in all radiotherapy, surgery, and pharmacological approaches. It is advisable to conduct a careful nephrological follow-up imposing the application of body surface based estimated Glomerular Filtration Rate (eGFR) formulas for the purpose of an early diagnosis and treatment of renal failure, guaranteeing the therapy continuation to thyroid cancer patients.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Lenvatinib dose reduction to 10 mg/day was not able to resolve the nephrotic syndrome. Conversely, the Lenvatinib substitution with Sorafenib 400 mg/day induced a complete remission of the nephrotic syndrome in the absence of cancer progression at 5-month follow-up [ 65 ].…”

Section: Biological Agentsmentioning

confidence: 99%

Impact of Thyroid Cancer Treatment on Renal Function: A Relevant Issue to Be Addressed

Paola

Capasso

et al. 2023

JPM

View full text Add to dashboard Cite

show abstract

“…In addition to the tumor itself, treatment of the tumor may also be responsible for inducing NS in patients. Yang et al [ 11 ] have reported a patient with PTC who developed NS after lenvatinib treatment. The second patient reported in the present study could represent one such case.…”

Section: Discussionmentioning

confidence: 99%

Minimal change disease with papillary thyroid carcinoma: a report of two adult cases

Yin

Hao

et al. 2023

BMC Nephrol

View full text Add to dashboard Cite

Background Minimal change disease (MCD), a pathological type of nephrotic syndrome (NS), can occur in patients with tumors. We report two adult cases of MCD associated with papillary thyroid carcinoma (PTC), known to be extremely rare in adults. Case presentation A 35-year-old female patient was simultaneously diagnosed with MCD and PTC. The MCD was effectively treated with thyroidectomy and prednisone.In addition, a 50-year-old male patient, who had been diagnosed with PTC three years prior, had MCD confirmed by renal biopsy. The patient achieved complete remission following treatment with tacrolimus and rituximab. Conclusions The present case report describes and discusses the diagnostic and treatment processes employed in these two patients. Clinicians need to be aware of the renal effects of treating patients with solid tumors.

show abstract

Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer

Yokota,

Hamauchi,

Kawakami

et al. 2024

Invest New Drugs

View full text Add to dashboard Cite

Improvement of lenvatinib-induced nephrotic syndrome after adaptation to sorafenib in thyroid cancer: A case report

Cited by 6 publications

References 19 publications

Impact of Thyroid Cancer Treatment on Renal Function: A Relevant Issue to Be Addressed

Impact of Thyroid Cancer Treatment on Renal Function: A Relevant Issue to Be Addressed

Minimal change disease with papillary thyroid carcinoma: a report of two adult cases

Lenvatinib rechallenge after failure of lenvatinib and sorafenib in metastatic thyroid cancer

Contact Info

Product

Resources

About